Friday, June 15, 2018 10:26:51 AM
>>>Mymetics(otcqb:MYMX) - Sanofi Pasteur [vaccine unit of Sanofi(nyse:SNY)]<<<
short term catalyst ~June 2018 collaboration result/decision point!
Mymetics' (OTCQB:MYMX) extremely undervalued @ $ 0.04
>>> Vaccine Pipeline:
HIV
Malaria
Intranasal Influenza
RSV
Chikungunya
>>> Partnerships:
Anergis ---------------------------------------------------------- April 2018 - present
Sanofi Pasteur (vaccine unit of Sanofi : NYSE: SNY) --- Oct.2016 - present
Astellas Pharma (2nd Largest Japanese Pharma Co.)-- Jan.2014 - July 2016
Catalent (NYSE:CTLT) ---April 2015 - Present
Bachem (SIX:BANB) ------April 2015 - Present
Upperton, UK -------------- April 2015 - Present
Chimera Biotec, Germany-April 2015 - Present
Texas Biomedical Research Institute - Sept.2014 - Present
>>> Funding Organizations:
Bill & Melinda Gates Foundation - HIV-1 vaccine
PATH MVI ------------------------------ Malaria Transmission Blocking Vaccine
Swiss Tropical & Public Health Institute --- Malaria Vaccine
European Union Horizon 2020---------------MACIVIVA (Manufacturing Process For Cold-Chain Independent Virosome based Vaccines)-- Mymetics is leading a consortium of 4 other companies.
**** MACIVIVA *****
>>> MACIVIVA = Game Changer = Disrupting the vaccine industry worldwide!
MACIVIVA latest Progress' Reporting Period Posted: https://cordis.europa.eu/result/rcn/194900_en.html
Copy of latest MACIVIVA presentation (downloadable): https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/
>>> No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry
http://investor.catalent.com/press-release/financial-news/no-more-pricks-%E2%80%93-quick-dissolvable-tablet-set-disrupt-vaccine-industry https://vimeo.com/217946374<<< click video insert
>>> Dr. Christopher Henney, currently Anthera Pharmaceuticals(ANTH) and Cascadian Therapeutics (formerly Oncothyreon) - recently acquired by Seattle Genetics, Chairman of the Board; Director at Cyclacel Pharmaceuticals and former Dendreon co-founder & CEO was once on board with this unknown microcap as Chairman of BOD but seems had a disagreement with the largest shareholder that led him and his Dendreon protege to leave in less than a year.
https://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/
Share Structure:
Outstanding : 303.7million common shares (unchanged since 2014)
Float: ~ 91 million shares
>>> MYMX is leading this disruptive project.
https://cordis.europa.eu/docs/results/h2020/646/646122_PS/maciviva-project-concept.jpg
"click" on Company Overview: https://www.mymetics.com/about/
****taken from yahoo message board courtesy of nito****
Recent SNY News
- Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD • GlobeNewswire Inc. • 09/27/2024 01:35:08 PM
- Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) • GlobeNewswire Inc. • 09/27/2024 11:00:04 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/24/2024 06:51:56 PM
- Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More • IH Market News • 09/23/2024 10:32:25 AM
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old • GlobeNewswire Inc. • 09/20/2024 11:45:00 AM
- Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA • PR Newswire (US) • 09/16/2024 12:00:00 PM
- Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) • GlobeNewswire Inc. • 09/13/2024 04:15:28 PM
- Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares • Business Wire • 09/12/2024 06:37:00 AM
- Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement on Next-Generation Radioligand Medicine for Rare Cancers • Business Wire • 09/12/2024 06:37:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/13/2024 01:06:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 10:30:03 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 10:05:25 AM
- Le vaccin FluzoneMD Haute Dose Quadrivalent demeure le vaccin préférentiellement recommandé pour protéger les adultes de 65 ans et plus contre la grippe • PR Newswire (Canada) • 07/26/2024 04:08:00 PM
- Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza • PR Newswire (Canada) • 07/26/2024 03:17:00 PM
- Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% • IH Market News • 07/25/2024 10:19:48 AM
- Sanofi ships U.S. influenza vaccines for the 2024/25 season • PR Newswire (US) • 07/10/2024 08:10:00 PM
- BP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More News • IH Market News • 07/09/2024 10:54:32 AM
- Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine • GlobeNewswire Inc. • 06/26/2024 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/11/2024 05:54:55 PM
- I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/31/2024 08:30:55 PM
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD • GlobeNewswire Inc. • 05/31/2024 05:05:00 AM
- Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation • GlobeNewswire Inc. • 05/31/2024 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 08:30:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 04:04:28 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM